Multiple Myeloma

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment [Phase 3]

  This entry describes a Phase 3 trial evaluating talquetamab in combination with daratumumab (or with daratumumab and pomalidomide) versus da…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma [Phase 2]

  A Phase 2 study of JNJ-68284528, a BCMA-targeted CAR-T therapy, in participants with multiple myeloma is currently active but not recruiting…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis [Phase 1]

  This Phase 1 study of JNJ-79635322 in relapsed or refractory multiple myeloma and previously treated AL amyloidosis is currently recruiting.…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma [Phase 1]

  Phase 1 clinical trial update on QXL138AM assessing safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors and mul…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse [Phase 2]

  Phase 2 clinical trial assessing the investigational combination of daratumumab and teclistamab versus standard regimens in high-risk relaps…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  This entry reports a clinical trial studying real-world current standards of care for participants with relapsed or refractory multiple myel…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating the safety and anti-tumor activity of REGN7945 in combination with Linvoseltamab in adults with relaps…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

  A phase 1 clinical trial investigating pre- and post-change Teclistamab in participants with relapsed or refractory multiple myeloma is curr…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma [Phase 1]

  Phase 1 trial update investigating teclistamab in combination with iberdomide for relapsed or refractory multiple myeloma, currently recruit…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) [Phase 2]

  This Phase 2 MATCH Screening Trial update describes ongoing evaluation of targeted therapies matched to genetic alterations in patients with…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

  Phase 1 clinical trial evaluating talquetamab and teclistamab, each in combination with a PD-1 inhibitor, for relapsed or refractory multipl…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

  Prospective collection, storage, and reporting of data on patients undergoing hematopoietic stem cell transplantation using a standard prepa…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma [Phase 2]

  A Phase 2 trial evaluating a quadruplet combination of daratumumab, carfilzomib, lenalidomide, and low-dose dexamethasone (DKRd) in newly di…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

  This clinical trial update describes a Phase 1/2 study of Teclistamab in Japanese participants with relapsed or refractory multiple myeloma.…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

  This document announces a Phase 2 clinical trial evaluating JNJ-79635322 in relapsed or refractory multiple myeloma and notes that it is cur…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

  A Phase 1 clinical trial evaluating the safety and tolerability of OPN-6602 in subjects with relapsed or refractory multiple myeloma is curr…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma [Phase 1]

  This Phase 1 trial evaluates JNJ-79635322 in combination with daratumumab, with or without lenalidomide, or in combination with pomalidomide…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

  Phase 1 clinical trial assessing pharmacokinetics, safety, and efficacy of cevostamab in Chinese participants with relapsed or refractory mu…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel [Phase 4]

  A Phase 4 long-term follow-up trial for patients who were previously treated with cilta-cel (cilta-cabtagene autoleucel) for multiple myelom…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Daratumumab [Phase 3]

  A Phase 3 clinical trial investigating daratumumab for multiple myeloma is currently recruiting.

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  A clinical trial update about outcomes in relapsed/refractory multiple myeloma patients treated with T-cell redirectors outside of clinical …

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma [Phase 2]

  Phase 2 clinical trial update comparing Dara-SVD (daratumumab, selinexor, bortezomib, dexamethasone) with Dara-RVD (daratumumab, lenalidomid…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  A multicenter protocol to improve access and distribution of unlicensed cryopreserved cord blood units, with the study currently recruiting.…

• CLINICAL_TRIALS research · 2026-04-09
  Clinical Trial Update: Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

  The document provides a clinical trial update from the University of Miami describing two distinct precursor states of multiple myeloma—prog…

• CLINICAL_TRIALS research · 2026-04-09
  Clinical Trial Update: Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

  A clinical trial is evaluating Zn-DDC to target the Hypoxia-NFkappaB-CSCs pathway in multiple myeloma. Recruitment is ongoing.